218 related articles for article (PubMed ID: 22195686)
1. Clinical efficacy of omalizumab in an elderly veteran population with severe asthma.
Verma P; Randhawa I; Klaustermeyer WB
Allergy Asthma Proc; 2011; 32(5):346-50. PubMed ID: 22195686
[TBL] [Abstract][Full Text] [Related]
2. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
3. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
Molimard M; Mala L; Bourdeix I; Le Gros V
Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.
Storms W; Bowdish MS; Farrar JR
Allergy Asthma Proc; 2012; 33(2):172-7. PubMed ID: 22525394
[TBL] [Abstract][Full Text] [Related]
5. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
6. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
7. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.
de Llano LP; Vennera Mdel C; Álvarez FJ; Medina JF; Borderías L; Pellicer C; González H; Gullón JA; Martínez-Moragón E; Sabadell C; Zamarro S; Picado C;
J Asthma; 2013 Apr; 50(3):296-301. PubMed ID: 23350994
[TBL] [Abstract][Full Text] [Related]
8. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
9. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
11. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
[TBL] [Abstract][Full Text] [Related]
13. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
14. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.
Gouder C; West LM; Montefort S
Int J Clin Pharm; 2015 Feb; 37(1):36-43. PubMed ID: 25394832
[TBL] [Abstract][Full Text] [Related]
15. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
16. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland.
Subramaniam A; Al-Alawi M; Hamad S; O'Callaghan J; Lane SJ
QJM; 2013 Jul; 106(7):631-4. PubMed ID: 23550166
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
18. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
Chen H; Eisner MD; Haselkorn T; Trzaskoma B
Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
[TBL] [Abstract][Full Text] [Related]
19. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
20. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]